Pet Health Company Elanco Animal Stock Plunges On Guiding Below Consensus

  • Elanco Animal Health Inc ELAN has reported Q2 EPS of $0.28 higher than $0.09 reported a year ago, surpassing analysts' estimate of $0.26 and the company guidance of $0.22 - $0.27.
  • Sales of $1.28 billion, +118% Y/Y, were above the guidance range of $1.23 - $1.26 billion, beating the consensus estimate of $1.23 billion.
  • The growth was driven by the inclusion of the Bayer Animal Health business.
  • Legacy Elanco's revenue was $750 million (+28% Y/Y). $529 million in sales came from the legacy Bayer Animal Health portfolio.
  • Pet Health's revenue increased 54% to $685 million. Farm Animal revenue increased 44% for the quarter to $567 million.
  • The gross margin compressed from 50.5% to 43.1%.
  • Guidance Q3 2021: Elanco expects revenue of $1.08 billion - $1.1 billion, versus the analyst consensus of $1.09 billion.
  • It expects adjusted EPS of $0.15 - $0.19 (consensus of $0.20) and adjusted EBITDA of $195 million - $220 million.
  • FY21 Guidance: Elanco revised revenue guidance to $4.68 - $4.73 billion (consensus of 4.71 billion) from $4.67 billion - $4.71 billion
  • It expects an adjusted EPS outlook of $0.97 - $1.0 (consensus $1.04), down from prior guidance of $1.00 - $1.06.
  • It also lowered adjusted EBITDA guidance to $1.04 billion - $1.08 billion from $1.055 - $1.095 billion.
  • Price Action: ELAN shares are down 14% at $30.40 on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceShort IdeasHealth CareMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!